Xyzal Nasal Spray contains Fluticasone Furoate 27.5 mcg, a potent corticosteroid indicated for the treatment of allergic rhinitis and other inflammatory nasal conditions. This intranasal corticosteroid exerts its effects by inhibiting multiple types of cells and mediators involved in the inflammatory response, thereby reducing nasal congestion, sneezing, rhinorrhea, and nasal itching. Xyzal Nasal Spray is administered once daily, providing sustained relief of symptoms associated with seasonal and perennial allergic rhinitis. The formulation ensures targeted delivery to the nasal mucosa, minimizing systemic absorption and reducing the risk of systemic corticosteroid-related side effects. Clinical studies have demonstrated its efficacy in improving nasal airflow and decreasing mucosal inflammation with a favorable safety profile. Common adverse reactions may include nasal irritation, dryness, or epistaxis, which are generally mild and transient. Patients with a history of hypersensitivity to fluticasone furoate or any component of the formulation should avoid use. Caution is advised in individuals with active or quiescent tuberculosis, untreated fungal, bacterial, or viral infections of the respiratory tract. Xyzal Nasal Spray should be used under medical supervision, with adherence to prescribed dosage to optimize therapeutic outcomes and minimize potential adverse effects.